PTCT Q3 2021 Earnings — PTC Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTCTPTC Therapeutics, Inc.

$5B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$139M+17.2% YoY

Gross Profit

$132M95.3% margin

Operating Income

-$93M-67.1% margin

Net Income

-$134M-96.3% margin

EPS (Diluted)

$-1.89

QoQ Revenue Growth

+18.9%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$77M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$1.9B

Stockholders' Equity

$105M

Cash & Equivalents

$190M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$139M	$118M	+17.2%
Gross Profit	$132M	$114M	+16.2%
Operating Income	-$93M	-$55M	-68.8%
Net Income	-$134M	-$70M	-91.7%

Geographic Segments

Non Us

$67M59%

U

$47M41%